Abstract: The present invention relates to a pharmaceutical composition containing a G protein coupled receptor 119 (GPR119) ligand as an effective ingredient for preventing or treating non-alcoholic steatohepatitis. More particularly, it was confirmed that the GPR119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the GPR119 ligand can be useful to treat non-alcoholic steatohepatitis.
Type:
Application
Filed:
July 19, 2018
Publication date:
January 10, 2019
Applicant:
PHARMEDIX.CO., LTD.
Inventors:
Keon Wook KANG, Kyeong LEE, Jin Won YANG
Abstract: Provided is a pharmaceutical composition for preventing or treating liver fibrosis, comprising a GPR119 ligand as an active ingredient. The composition comprising the GPR119 ligand as an active ingredient significantly inhibits the expression of collagen I, transforming growth factor ? (TGF?) and ?-smooth muscle actin (?-SMA), thereby inhibiting HSC activation, and also significantly inhibits HSC proliferation. Therefore, the composition may be effectively applied in improvement, prevention, inhibition or treatment of liver fibrosis.
Type:
Grant
Filed:
November 18, 2016
Date of Patent:
February 20, 2018
Assignee:
PHARMEDIX.CO., LTD
Inventors:
Keon Wook Kang, Kyeong Lee, Jin Won Yang